Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Graham Osborn who wrote (58045)	9/22/2016 8:51:09 AM
From: Micah Lance	Respond to of 78659

Marc Cohodes is the main guy I have been following who is shorting CXRX. He says it is exactly like VRX, and the company is currently suing him for the issues he has brought up, which might be one of the largest red flags out there. Another major issue to bring up, the UK recently either proposed or passed a law that targets companies that raise drug prices without merit following all the issues going on with VRX and MYL. Once it was announced, CXRX dropped 18% so I can't imagine CXRX will have the ability to continue their current "business model." On the topic of VRX, it was recently reported they have a capital shortfall of nearly $1B. I think I saw they are listing an asset or two for sale to cover this shortfall, which is probably the only way they can cover this need as their debt load is becoming more and more unsustainable.